TY - JOUR

T1 - Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

AU - Rebbeck, Timothy R

AU - Friebel, Tara M

AU - Friedman, Eitan

AU - Hamann, Ute

AU - Huo, Dezheng

AU - Kwong, Ava

AU - Olah, Edith

AU - Olopade, Olufunmilayo I

AU - Solano, Angela R

AU - Teo, Soo-Hwang

AU - Thomassen, Mads

AU - Weitzel, Jeffrey N

AU - Chan, T L

AU - Couch, Fergus J

AU - Goldgar, David E

AU - Kruse, Torben A

AU - Palmero, Edenir Inêz

AU - Park, Sue Kyung

AU - Torres, Diana

AU - van Rensburg, Elizabeth J

AU - McGuffog, Lesley

AU - Parsons, Michael T

AU - Leslie, Goska

AU - Aalfs, Cora M

AU - Abugattas, Julio

AU - Adlard, Julian

AU - Agata, Simona

AU - Aittomäki, Kristiina

AU - Andrews, Lesley

AU - Andrulis, Irene L

AU - Arason, Adalgeir

AU - Arnold, Norbert

AU - Arun, Banu K

AU - Asseryanis, Ella

AU - Auerbach, Leo

AU - Azzollini, Jacopo

AU - Balmaña, Judith

AU - Barile, Monica

AU - Barkardottir, Rosa B

AU - Barrowdale, Daniel

AU - Benitez, Javier

AU - Berger, Andreas

AU - Berger, Raanan

AU - Blanco, Amie M

AU - Blazer, Kathleen R

AU - Blok, Marinus J

AU - Bonadona, Valérie

AU - Ejlertsen, Bent

AU - Gerdes, Anne-Marie

AU - Nielsen, Finn Cilius

AU - EMBRACE

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018

Y1 - 2018

N2 - The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.

AB - The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.

U2 - 10.1002/humu.23406

DO - 10.1002/humu.23406

M3 - Journal article

C2 - 29446198

VL - 39

SP - 593

EP - 620

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 5

ER -